Gilead’s History

Transforming Treatment in HIV and Hep C

Over the last three decades we’ve created revolutionary therapies for people living with HIV and Hepatitis C, and developed a reputation for innovation that’s second to none.



We pioneered the first single tablet HIV regimen and developed the first medicine to prevent HIV infection.

Hepatitis C

We introduced four medicines in less than four years that offer a cure for the majority of people living with chronic Hepatitis C.


Ranked number 1 in the 2019 Pharmaceutical Innovation Index.

Our Impact, by the Numbers Worldwide


130 countries

Patients in over 130 countries reached with our treatment programs, in collaboration with international and local partners on the ground

27 marketed drugs

27 marketed drugs and an active R&D program1


11.5 million

An estimated 11.5 million people in resource-limited countries take an HIV regimen containing a Gilead medication2

Liver Diseases

3.2 million

3.2 million people treated by Gilead HCV curative regimens3


Galapagos’ Vision

Pioneering Research to Create Unique Targeted Therapies

Driven by a need to make great things happen, we’ve used state-of-the-art human biotechnology to discover and develop unique therapies.



A bold and agile approach to drug discovery, powered by the philosophy: If it doesn’t happen, make it happen.


Cutting-edge biotech that uses human cells from patients to discover novel targets for medicines to beat severe diseases.


A unique discovery platform that uses a vast adenoviral library to identify specific protein targets at the root cause of chronic disease, develop small molecule therapies aimed at those novel targets, and bring molecules rapidly to clinical trials.